LoginSignup
Regeneron Pharms logo

Regeneron Pharms

Stock
Stock
ISIN: US75886F1075
Ticker: REGN
US75886F1075
REGN

Price

Price

Frequently asked questions

What is Regeneron Pharms's market capitalization?

The market capitalization of Regeneron Pharms is $81.81B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.

What is Regeneron Pharms's Price-to-Earnings (P/E) ratio?

The Price-to-Earnings (P/E) ratio (TTM) for Regeneron Pharms is 18.42. This ratio helps investors assess whether a stock is overvalued or undervalued compared to its earnings.

What is the Earnings Per Share (EPS) for Regeneron Pharms?

Regeneron Pharms's Earnings Per Share (EPS) over the trailing twelve months (TTM) is $40.42. EPS indicates the company's profitability on a per-share basis.

What are the analyst ratings and target price for Regeneron Pharms's stock?

Currently, 28 analysts cover Regeneron Pharms's stock, with a consensus target price of $1,066.47. Analyst ratings provide insights into the stock's expected performance.

What is Regeneron Pharms's revenue over the trailing twelve months?

Over the trailing twelve months, Regeneron Pharms reported a revenue of $13.85B.

What is the EBITDA for Regeneron Pharms?

Regeneron Pharms's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $4.66B. EBITDA measures the company's overall financial performance.

What is the free cash flow of Regeneron Pharms?

Regeneron Pharms has a free cash flow of $3.32B. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.

What is the 5-year beta of Regeneron Pharms's stock?

The 5-year beta for Regeneron Pharms is 0.09. A beta value indicates the stock's volatility relative to the market; a beta greater than 1 means higher volatility.

How many employees does Regeneron Pharms have, and what sector and industry does it belong to?

Regeneron Pharms employs approximately 13,450 people. It operates in the Health Care sector, specifically within the Biotechnology & Drugs industry.

What is the free float of Regeneron Pharms's shares?

The free float of Regeneron Pharms is 106.38M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap

 $81.81B

5Y beta

 0.09

EPS (TTM)

 $40.42

Free Float

 106.38M

P/E ratio (TTM)

 18.42

Revenue (TTM)

 $13.85B

EBITDA (TTM)

 $4.66B

Free Cashflow (TTM)

 $3.32B

Pricing

1D span
$745.09$746.45
52W span
$736.01$1,211.20

Analyst Ratings

The price target is $1,066.47 and the stock is covered by 28 analysts.

Buy

20

Hold

7

Sell

1

Information

Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company helps in accelerating and improving the traditional drug development process through its VelociSuite technologies, such as VelocImmune, which uses genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center. Its marketed products include EYLEA (aflibercept) Injection; Dupixent (dupilumab) Injection; Libtayo (cemiplimab) Injection; Praluent (alirocumab) Injection; Kevzara (sarilumab) Injection, and others.

13,450

Biotechnology & Drugs

Health Care

Identifier

ISIN

US75886F1075

Primary Ticker

REGN

Knockouts

Join the conversation
Sign upLogin